The EC has published the long-awaited revised Market Definition Notice (the "Notice"), marking the first update since its initial adoption in 1997. The Notice clarifies the methodology for defining product and geographic...more
On 10 March 2020 the Court of Appeal upheld the Competition Appeal Tribunal's (CAT) quashing of the Competition and Markets Authority's (CMA) decision that Pfizer and Flynn Pharma (Flynn) had abused their dominant positions...more
4/1/2020
/ Abuse of Dominance ,
Appeals ,
Drug Pricing ,
Evidence ,
Excessive Pricing ,
Pfizer ,
Reaffirmation ,
Standard of Review ,
UK ,
UK Competition and Markets Authority (CMA) ,
UK Competition Appeal Tribunal (CAT)
Setting the scene
The long anticipated European Commission (DG COMP) report on "EU loan syndication and its impact on competition in credit markets" (see here) has finally been published. The study primarily focuses on the...more
4/15/2019
/ Anticompetitive Agreements ,
Banks ,
Borrowers ,
Competition ,
Contract Negotiations ,
Contract Terms ,
Duty of Care ,
EU ,
European Commission ,
France ,
Germany ,
Hedging ,
Impact Assessments ,
Information Reports ,
Infrastructure ,
Interest Rates ,
Lenders ,
Leveraged Buyout ,
Loans ,
Netherlands ,
Poland ,
Risk Management ,
Spain ,
Syndicated Loans ,
UK
On 14 March 2019, the UK Competition and Markets Authority (CMA) decided to close its investigation into a discount scheme by Merck Sharp & Dohme Limited (MSD). The CMA concluded that there were no grounds for it to take...more